Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
In the latest session, Xeris Biopharma Holdings Inc (NASDAQ: XERS) closed at $6.73 up 4.02% from its previous closing price of $6.47. In other words, the price has increased by $4.02 from its previous closing price. On the day, 2.45 million shares were traded. XERS stock price reached its highest trading level at $6.85 during the session, while it also had its lowest trading level at $6.5.
Ratios:
For a deeper understanding of Xeris Biopharma Holdings Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 12.19 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 112.00. For the most recent quarter (mrq), Quick Ratio is recorded 1.35 and its Current Ratio is at 1.93.
On November 11, 2024, Piper Sandler Downgraded its rating to Neutral which previously was Overweight but kept the price unchanged to $3.
On March 28, 2024, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $5.Oppenheimer initiated its Outperform rating on March 28, 2024, with a $5 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 01 ’25 when Hecht Beth sold 16,667 shares for $7.01 per share. The transaction valued at 116,781 led to the insider holds 1,320,176 shares of the business.
Shannon John Patrick Jr sold 23,242 shares of XERS for $173,402 on Nov 13 ’25. The insider now owns 2,643,153 shares after completing the transaction at $7.46 per share. On Nov 11 ’25, another insider, Hecht Beth, who serves as the insider of the company, sold 16,667 shares for $7.40 each. As a result, the insider received 123,296 and left with 1,336,843 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XERS now has a Market Capitalization of 1116670464 and an Enterprise Value of 1282726528. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.20. Its current Enterprise Value per Revenue stands at 4.82 whereas that against EBITDA is 45.753.
Stock Price History:
The Beta on a monthly basis for XERS is 0.66, which has changed by 0.73458445 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, XERS has reached a high of $10.08, while it has fallen to a 52-week low of $3.14. The 50-Day Moving Average of the stock is -17.61%, while the 200-Day Moving Average is calculated to be 11.10%.
Shares Statistics:
For the past three months, XERS has traded an average of 2.37M shares per day and 1844250 over the past ten days. A total of 165.53M shares are outstanding, with a floating share count of 154.64M. Insiders hold about 6.80% of the company’s shares, while institutions hold 58.99% stake in the company. Shares short for XERS as of 1763078400 were 15746194 with a Short Ratio of 6.65, compared to 1760486400 on 17850615. Therefore, it implies a Short% of Shares Outstanding of 15746194 and a Short% of Float of 9.86.
